PATENT CLAIM ANALYSIS

Application Number: 16165833
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-05
Patent Classification: ["424", "130100"]

Abstract:
The instant disclosure provides antibodies that specifically bind to human CTLA-4 and antagonize CTLA-4 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

Claim (Index 130):
A pharmaceutical composition comprising the antibody of  claim 118  and a pharmaceutically acceptable carrier or excipient.

Metadata:
- Claim Count in Document: 107.0
- Percentile: 97.0
- Lexical Diversity: 1.34211
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15166305', '15254315', '09948939', '15148720', '10207655']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.73116577955332
- 35 USC 102 Novelty (BERT): 0.6086934706705726
- Combined Prediction Score: 0.7189185486650452
- Mean Citation Score: 432.662276
- Max Citation Score: 556.3441
- Similarity Product: 443.5393165183902

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test